Birkenfeld, A.L. & Bergman, M.* Bodyweight loss and remission of type 2 diabetes. Lancet Diabet. Endocrinol. 13, 265-267 (2025)
Bornstein, S.R. et al. Artificial intelligence and diabetes: Time for action and caution. Lancet Diabet. Endocrinol. 13, 552-554 (2025)
Hummel, S. ; Köger, M. ; Bonifacio, E. & Ziegler, A.-G. Dysglycaemia definitions and progression to clinical type 1 diabetes in children with multiple islet autoantibodies. Lancet Diabet. Endocrinol. 13, 10-12 (2025)
Rubino, F.* et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabet. Endocrinol. 13, 221-262 (2025)
Stefan, N. ; Yki-Järvinen, H.* & Neuschwander-Tetri, B.A.* Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabet. Endocrinol. 13, 134-148 (2025)
Stefan, N. Does tirzepatide treatment improve skeletal muscle composition? Lancet Diabet. Endocrinol. 13, 455-457 (2025)
Bonifacio, E. ; Winkler, C. ; Achenbach, P. & Ziegler, A.-G. Effect of population-wide screening for presymptomatic early-stage type 1 diabetes on paediatric clinical care. Lancet Diabet. Endocrinol. 12, 376-378 (2024)
Sommer, J.* et al. Depression symptoms, wellbeing, health-related quality of life, and diabetes-related distress in novel subtypes of recent-onset diabetes in Germany: A 5-year observational follow-up study. Lancet Diabet. Endocrinol. 12, 890-903 (2024)
Stefan, N. ; Schiborn, C.* ; Machann, J. ; Birkenfeld, A.L. & Schulze, M.B.* Impact of higher BMI on cardiometabolic risk: Does height matter? Lancet Diabet. Endocrinol. 12, 514-515 (2024)
von Loeffelholz, C.* & Birkenfeld, A.L. Tight versus liberal blood-glucose control in the intensive care unit: Special considerations for patients with diabetes. Lancet Diabet. Endocrinol. 12, 277-284 (2024)
Dawed, A.Y.* et al. Pharmacogenomics of GLP-1 receptor agonists: A genome-wide analysis of observational data and large randomised controlled trials. Lancet Diabet. Endocrinol. 11, 33-41 (2023)
Hummel, J.* ; Kullmann, S. ; Wagner, R.* & Heni, M.* Glycaemic fluctuations across the menstrual cycle: Possible effect of the brain. Lancet Diabet. Endocrinol. 11, 883-884 (2023)
Körner, A. ; Stein, R. & Landgraf, K.* Beyond genetic screening-functionality-based precision medicine in monogenic obesity. Lancet Diabet. Endocrinol. 11, 143-144 (2023)
Perakakis, N. et al. Mechanisms and clinical relevance of the bidirectional relationship of viral infections with metabolic diseases. Lancet Diabet. Endocrinol. 11, 675-693 (2023)
Sandforth, A. et al. Mechanisms of weight loss-induced remission in people with prediabetes: A post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS). Lancet Diabet. Endocrinol. 11, 798-810 (2023)
Schön, M.* et al. Analysis of type 2 diabetes heterogeneity with a tree-like representation: Insights from the prospective German Diabetes Study and the LURIC cohort. Lancet Diabet. Endocrinol. 12, 119-131 (2023)
Stefan, N. & Schulze, M.B.* Metabolic health and cardiometabolic risk clusters: Implications for prediction, prevention, and treatment. Lancet Diabet. Endocrinol. 11, 426-440 (2023)
Stefan, N. & Schulze, M.B.* Achieving replicable subphenotypes of adult-onset diabetes - Authors' reply. Lancet Diabet. Endocrinol. 11, 636-637 (2023)
Bechmann, N.* et al. Sexual dimorphism in COVID-19: Potential clinical and public health implications. Lancet Diabet. Endocrinol. 10, 221-230 (2022)
Ghalwash, M.* et al. Two-age islet-autoantibody screening for childhood type 1 diabetes: A prospective cohort study. Lancet Diabet. Endocrinol. 10, 589-596 (2022)
Stefan, N. & Cusi, K.* A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabet. Endocrinol. 10, 284-296 (2022)
Steenblock, C.* et al. COVID-19 and metabolic disease: Mechanisms and clinical management. Lancet Diabet. Endocrinol. 9, 786-798 (2021)
Bornstein, S.R. et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabet. Endocrinol. 8, 546-550 (2020)
Kullmann, S. et al. Central nervous pathways of insulin action in the control of metabolism and food intake. Lancet Diabet. Endocrinol. 8, 524-534 (2020)
Kurz, C.F. & König, A. The causal influence of maternal obesity on preterm birth. Lancet Diabet. Endocrinol. 8, 101-103 (2020)
Rubino, F.* et al. Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. Lancet Diabet. Endocrinol. 8, 640-648 (2020)
Rubino, F. ; Zimmet, P.* & Ludwig, B. Management of diabetes in patients with COVID-19 – Authors' reply. Lancet Diabet. Endocrinol. 8, 669-670 (2020)
Stefan, N. Causes, consequences, and treatment of metabolically unhealthy fat distribution. Lancet Diabet. Endocrinol. 8, 616-627 (2020)
Tofte, N.* et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): A prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabet. Endocrinol. 8, 301-312 (2020)
Turcu, A.F.* & Walch, A.K. A multi-test strategy for adrenal tumours. Lancet Diabet. Endocrinol. 8, 733-734 (2020)
Stefan, N. ; Häring, H.-U. & Cusi, K.* Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabet. Endocrinol. 7, 313-324 (2019)
Zaharia, O.P.* et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: A 5-year follow-up study. Lancet Diabet. Endocrinol. 7, 684-694 (2019)
Eckel, N.* et al. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses' Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabet. Endocrinol. 6, 714-724 (2018)
Dandona, P.* et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabet. Endocrinol. 5, 864-876 (2017)
Stefan, N. ; Häring, H.-U. & Schulze, M.B.* Metabolically healthy obesity: The low-hanging fruit in obesity treatment? Lancet Diabet. Endocrinol. 6, 249-258 (2017)
EUMODIC Consortium (Peters, A. ; Heid, I.) Natriuretic peptides and integrated risk assessment for cardiovascular disease: An individual-participant-data meta-analysis. Lancet Diabet. Endocrinol. 4, 840-849 (2016)
Stefan, N. ; Häring, H.-U. ; Hu, F.B.* & Schulze, M.B.* Divergent associations of height with cardiometabolic disease and cancer: Epidemiology, pathophysiology, and global implications. Lancet Diabet. Endocrinol. 4, 457-467 (2016)
Stefan, N. ; Fritsche, A. ; Schick, F. & Häring, H.-U. Phenotypes of prediabetes and stratification of cardiometabolic risk. Lancet Diabet. Endocrinol. 4, 789-798 (2016)
Interleukin 1 Genetics Consortium et al. Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: A mendelian randomisation analysis. Lancet Diabet. Endocrinol. 3, 243-253 (2015)
Chambers, J.C.* et al. Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: A nested case-control study. Lancet Diabet. Endocrinol. 3, 526-534 (2015)
NCD Risk Factors Collaboration (Müller-Nurasyid, M. ; Peters, A. ; Stöckl, D. ; Ezzati, M.*) Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: A pooled analysis of 96 population-based studies with 331 288 participants. Lancet Diabet. Endocrinol. 3, 624-637 (2015)
Schmid, S.M.* ; Hallschmid, M. & Schultes, B.* The metabolic burden of sleep loss. Lancet Diabet. Endocrinol. 3, 52-62 (2015)
Stefan, N.* et al. Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: A multicentre, randomised, double-blind, placebo-controlled trial. Lancet Diabet. Endocrinol. 2, 406-416 (2014)
Vimaleswaran, K.S.* et al. Association of vitamin D status with arterial blood pressure and hypertension risk: A mendelian randomisation study. Lancet Diabet. Endocrinol. 2, 719-729 (2014)
Stefan, N. ; Häring, H.-U. ; Hu, F.B.* & Schulze, M.B. Metabolically healthy obesity: Epidemiology, mechanisms, and clinical implications. Lancet Diabet. Endocrinol. 1, 152-162 (2013)